PGEN Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Precigen, Inc. had $9.7M of revenue in fiscal 2025, up 146.7% on the year before. Over five years, revenue changed β21.3% a year on average.
Last close Β· Oct 23, 2026
$6.19
3.1%Hi! I read Precigen, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+146.7%
Yes. Sales grew 146.7% last year.
Does it make a profit?
β2,588.2%
No. It lost money last year.
Does profit turn into cash?
β927.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Precigen, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 4, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 13, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 25, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 13, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 12, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 14, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 19, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 14, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Precigen, Inc. had $9.7M of revenue in fiscal 2025, up 146.7% on the year before. Over five years, revenue changed β21.3% a year on average. Its operating margin was β1,141.1%, up 2,299.1Β pts: of every 100 in sales, about β1,141 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Precigen, Inc. lost $251M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$89.8M in fiscal 2025, β927.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Precigen, Inc. has $4.7M more cash than debt.
Cash, debt and the ratios that show how comfortably Precigen, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $109M | $56.0M | $62.9M | $97.9M | $97.9M |
| Debt incl. finance leases | $180M | $86.4M | $0.0M | $0.0M | $93.2M |
| Debt / equity | 1.7x | 0.7x | 0.0x | 0.0x | 4.5x |
| Interest coverage | β | β | β213.2x | β22,504.8x | β28.6x |
| Current ratio | 4.5x | 1.5x | 3.0x | 4.8x | 3.1x |
| Quick ratio | 4.5x | 1.5x | 3.0x | 4.8x | 3.1x |
| Total assets | $360M | $216M | $151M | $145M | $156M |
| Total liabilities | $253M | $89.7M | $32.5M | $78.5M | $135M |
| Shareholders' equity | $107M | $126M | $118M | $38.5M | $20.9M |
| Net debt (β = net cash) | $71.3M | $30.5M | β$62.9M | β$97.9M | β$4.7M |
KIRA Β· Its return on capital was β538.0%: every 100 invested in the business earned about β538 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Precigen, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 9 | 2 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 4 / 8 | 3 / 8 | 2 / 8 | 2 / 8 |
| Accruals ratio | β14.5% | β1.5% | β49.3% | β31.8% | β24.3% | β10.8% | 32.4% | β15.8% | β39.2% | β108.3% |
| Altman Z'' | β0.32 | β1.92 | β7.62 | β | β | β | β | β41.03 | β49.00 | β50.41 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $191M | $231M | $151M | $90.7M | $32.0M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M |
| Gross profit | $153M | $198M | β | β | β | β | β | β | β | β |
| Research and development | $112M | $143M | $405M | β | β | β | β | $48.6M | $53.1M | $41.3M |
| Operating income | β$125M | β$138M | β$506M | β | β | β | β | β$99.8M | β$135M | β$111M |
| Interest expense | $0.9M | $0.6M | $8.5M | β | β | β | β | $0.5M | $0.0M | $3.9M |
| Pretax income | β$194M | β$78.4M | β$396M | β$171M | β$105M | β$111M | β$80.0M | β$96.4M | β$128M | β$251M |
| Income tax | β$3.9M | $2.1M | β$15.4M | β$0.9M | β$0.1M | β$0.2M | β$0.2M | β$0.5M | β$1.8M | $0.0M |
| Net income | β$187M | β$117M | β$509M | β$322M | β$171M | β$92.2M | $28.3M | β$95.9M | β$126M | β$251M |
| Net income to common | β | β | β | β | β | β | β | β$95.9M | β$126M | β$430M |
| Diluted EPS | β$1.58 | β$0.98 | β$3.93 | β$2.09 | β$1.02 | β$0.47 | $0.14 | β$0.39 | β$0.47 | β$1.37 |
| Diluted shares | 0.12B | 0.12B | 0.13B | 0.15B | 0.17B | 0.20B | 0.20B | 0.24B | 0.27B | 0.31B |
| Cash flow | ||||||||||
| Cash from operations | β$49.0M | β$104M | β$124M | β$136M | β$77.0M | β$55.8M | β$65.0M | β$66.9M | β$68.2M | β$87.8M |
| Capital expenditure | $31.6M | $46.7M | $41.6M | $37.9M | $7.5M | $7.2M | $4.9M | $1.5M | $8.6M | $2.0M |
| Free cash flow | β$80.6M | β$150M | β$166M | β$174M | β$84.5M | β$63.0M | β$70.0M | β$68.5M | β$76.8M | β$89.8M |
| Depreciation and amortization | $24.6M | $31.1M | $33.1M | $24.9M | $17.5M | $13.8M | $10.8M | $6.7M | $4.5M | $3.2M |
| Stock-based compensation | $42.2M | $41.6M | $36.3M | $19.0M | $18.4M | $13.9M | $10.2M | $9.9M | $9.5M | $10.9M |
| Acquisitions | $0.0M | β$2.1M | $0.9M | $0.0M | $0.0M | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $237M | $74.4M | $216M | $75.1M | $100M | $109M | $56.0M | $62.9M | $97.9M | $97.9M |
| Total debt | $7.9M | $8.0M | $212M | $218M | $172M | $180M | $86.4M | $0.0M | $0.0M | $93.2M |
| Current assets | $315M | $154M | $285M | $235M | $149M | $157M | $118M | $68.8M | $102M | $115M |
| Current liabilities | $94.6M | $80.2M | $61.6M | $123M | $42.1M | $34.6M | $78.6M | $23.0M | $21.5M | $37.3M |
| Property and equipment, net | $64.7M | $113M | $86.9M | $44.0M | $34.9M | $8.6M | $7.3M | $7.1M | $13.8M | $13.8M |
| Goodwill | $157M | $93.8M | $93.6M | $54.1M | $54.4M | $37.6M | $36.9M | $26.6M | $19.1M | $15.2M |
| Intangible assets | $226M | $233M | $89.0M | $68.3M | $65.4M | $52.3M | $44.5M | $40.7M | $4.5M | $3.2M |
| Total assets | $949M | $847M | $716M | $456M | $315M | $360M | $216M | $151M | $145M | $156M |
| Total liabilities | $380M | $300M | $337M | $384M | $247M | $253M | $89.7M | $32.5M | $78.5M | $135M |
| Shareholders' equity | $560M | $534M | $363M | $71.7M | $67.2M | $107M | $126M | $118M | $38.5M | $20.9M |
| Margins | ||||||||||
| Gross margin | 80.2% | 85.6% | β | β | β | β | β | β | β | β |
| Operating margin | β65.6% | β59.7% | β334.4% | β | β | β | β | β1,602.5% | β3,440.2% | β1,141.1% |
| EBITDA margin | β52.7% | β46.2% | β312.5% | β | β | β | β | β1,495.4% | β3,324.9% | β1,108.1% |
| Net margin | β97.7% | β50.7% | β336.9% | β355.3% | β533.0% | β646.0% | 105.2% | β1,540.6% | β3,216.2% | β2,588.2% |
| FCF margin | β42.2% | β65.1% | β109.7% | β191.6% | β264.3% | β441.7% | β260.0% | β1,099.9% | β1,955.6% | β927.6% |
| Returns | ||||||||||
| Return on capital | β29.9% | β23.3% | β111.6% | β | β | β | β | β141.6% | β | β538.0% |
| Return on capital employed | β14.6% | β18.0% | β77.2% | β | β | β | β | β77.9% | β109.1% | β93.5% |
| Return on equity | β33.3% | β21.4% | β113.6% | β148.3% | β245.6% | β105.6% | 24.2% | β78.4% | β160.8% | β843.6% |
| Return on assets | β19.7% | β13.0% | β65.2% | β55.0% | β44.3% | β27.3% | 9.8% | β52.3% | β85.2% | β166.7% |
| Return on tangible equity | β105.2% | β56.5% | β282.5% | β | β | β526.6% | 63.1% | β187.4% | β846.1% | β17,206.3% |
| Growth | ||||||||||
| Revenue growth | β | 21.0% | β34.5% | β40.0% | β64.7% | β55.4% | 88.6% | β76.9% | β36.9% | 146.7% |
| Net income growth | β | β | β | β | β | β | β | β438.7% | β | β |
| EPS growth | β | β | β | β | β | β | β | β378.6% | β | β |
| Share count change | β | 1.7% | 7.9% | 19.0% | 8.4% | 18.4% | 1.3% | 22.0% | 9.5% | 16.9% |
| Financial health | ||||||||||
| Debt / equity | 0.0x | 0.0x | 0.6x | 3.0x | 2.6x | 1.7x | 0.7x | 0.0x | 0.0x | 4.5x |
| Interest coverage | β145.4x | β225.7x | β59.3x | β | β | β | β | β213.2x | β22,504.8x | β28.6x |
| Current ratio | 3.3x | 1.9x | 4.6x | 1.9x | 3.5x | 4.5x | 1.5x | 3.0x | 4.8x | 3.1x |
| Quick ratio | 3.3x | 1.9x | 4.6x | 1.9x | 3.5x | 4.5x | 1.5x | 3.0x | 4.8x | 3.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 16.6% | 20.2% | 27.5% | 41.8% | 23.5% | 50.8% | 18.3% | 24.7% | 218.7% | 20.6% |
| Stock comp / revenue | 22.1% | 18.0% | 24.0% | 20.9% | 57.4% | 97.5% | 37.9% | 158.8% | 241.3% | 112.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 2.0 | 2.0 | 3.0 | 4.0 | 4.0 | 3.0 | 2.0 | 2.0 |
| Altman Z'' | β0.3 | β1.9 | β7.6 | β | β | β | β | β41.0 | β49.0 | β50.4 |
| Accruals ratio | β14.5% | β1.5% | β49.3% | β31.8% | β24.3% | β10.8% | 32.4% | β15.8% | β39.2% | β108.3% |
Source: SEC EDGAR XBRL filings (CIK 0001356090). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
